Werner Syndrome RecQ Helicase-IN-3 CAS No.: 2869954-98-1

Chemical Structure : Werner syndrome RecQ helicase-IN-3

CAS No.: 2869954-98-1

 

Werner syndrome RecQ helicase-IN-3

Catalog No.: URK-V2495 Only Used For Lab.

Werner syndrome RecQ helicase-IN-3 (WRN-IN-3) is a small-molecule inhibitor that has been developed as a potential therapeutic for Werner syndrome. WRN-IN-3 works by selectively targeting the ATPase activity of WRN helicase, thereby inhibiting its DNA repair function and inducing apoptosis in cells that are deficient in WRN.

Biological Activity

Werner syndrome is a rare genetic disorder that affects multiple systems in the body, including the skin, bones, and nervous system. It is caused by mutations in the WRN gene, which encodes a RecQ helicase that plays a key role in DNA repair and maintenance. Individuals with Werner syndrome have a significantly increased risk of developing early onset age-related diseases, such as cancer, cardiovascular disease, and osteoporosis.
Several preclinical studies have demonstrated the potential of WRN-IN-3 as a therapeutic agent for Werner syndrome. For example, one study showed that WRN-IN-3 inhibited the growth of Werner syndrome fibroblasts in vitro and reduced the size of subcutaneous tumors in a mouse xenograft model of Werner syndrome-associated sarcoma. Another study found that WRN-IN-3 sensitized Werner syndrome cells to chemotherapeutic agents, suggesting that it could be used as an adjunct therapy to conventional cancer treatments.
While the development of WRN-IN-3 is still in the early stages, these preclinical studies provide valuable insights into its potential therapeutic applications. With further research and development, WRN-IN-3 could become an important tool in the fight against Werner syndrome and related diseases.

Physicochemical Properties

References

1. Halevy T, Akov S, Bohbot-Raviv Y, et al. Small molecule inhibitors of the werner syndrome recQ helicase exhibit genotoxicity in human cells. J Med Chem. 2012;55(16):7233-7243.

2. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature. 1998;396(6712):643-649.

3. Croteau DL, Popuri V, Opresko PL, et al. WRN suppresses the formation of large deletions from small deletions or non-homologous end joining. DNA Repair (Amst). 2013;12(9):618-628.

4. Chen Q, Van der Sluis PC, Navarro S, et al. Small molecule inhibitors and probes for werner syndrome recQ helicase. Mol Biosyst. 2013;9(3):311-317.

URK-V2495_COA

URk-V2495_SDS

URK-V2495_TDS

Hot Tags: Werner Syndrome RecQ Helicase-IN-3 CAS No.: 2869954-98-1, China Werner Syndrome RecQ Helicase-IN-3 CAS No.: 2869954-98-1, inhibitors for hormone regulation, inhibitors for scar formation, agonists in pharmaceutical research, epigenetic library for epigenetic regulation of cell senescence, epigenetic library for epigenetic analysis of histone modification, epigenetic library for epigenetic amplification